Skip to main content

Market Overview

Gemini Therapeutics Completes 60 Patients Enrollment In Lead Candidate Mid-Stage Study In Dry AMD

  • Gemini Therapeutics Inc (NASDAQ: GMTXconcludes enrollment in its Phase 2a ReGAtta study evaluating GEM103, a recombinant human complement factor H (CFH), in dry Age-related macular degeneration (AMD) patients with CFH loss-of-function gene variants.
  • The 60-subject trial is designed to evaluate safety and tolerability and measures of intraocular pharmacokinetics (PK) and disease-relevant biomarkers. Topline data anticipated in the first half of 2021.
  • The FDA granted Fast Track Designation for GEM103 to treat dry AMD in patients with CFH loss of function gene variants.
  • Price Action: GMTX shares moved 2.95% higher at 13.27 during market hours on the last check Wednesday.

Related Articles (GMTX)

View Comments and Join the Discussion!

Posted-In: Age-Related Macular Degeneration Phase 2A TrialBiotech News FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at